Meditation for the primary and secondary prevention of cardiovascular disease

医学 超验冥想 心理干预 冥想 物理疗法 注意 焦虑 随机对照试验 内科学 临床心理学 精神科 哲学 神学
作者
Karen Rees,Andrea Takeda,Rachel Court,Laura Kudrna,Louise Hartley,Edzard Ernst
出处
期刊:The Cochrane library [Wiley]
卷期号:2024 (2) 被引量:1
标识
DOI:10.1002/14651858.cd013358.pub2
摘要

Background Interventions incorporating meditation to address stress, anxiety, and depression, and improve self‐management, are becoming popular for many health conditions. Stress is a risk factor for cardiovascular disease (CVD) and clusters with other modifiable behavioural risk factors, such as smoking. Meditation may therefore be a useful CVD prevention strategy. Objectives To determine the effectiveness of meditation, primarily mindfulness‐based interventions (MBIs) and transcendental meditation (TM), for the primary and secondary prevention of CVD. Search methods We searched CENTRAL, MEDLINE, Embase, three other databases, and two trials registers on 14 November 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. Selection criteria We included randomised controlled trials (RCTs) of 12 weeks or more in adults at high risk of CVD and those with established CVD. We explored four comparisons: MBIs versus active comparators (alternative interventions); MBIs versus non‐active comparators (no intervention, wait list, usual care); TM versus active comparators; TM versus non‐active comparators. Data collection and analysis We used standard Cochrane methods. Our primary outcomes were CVD clinical events (e.g. cardiovascular mortality), blood pressure, measures of psychological distress and well‐being, and adverse events. Secondary outcomes included other CVD risk factors (e.g. blood lipid levels), quality of life, and coping abilities. We used GRADE to assess the certainty of evidence. Main results We included 81 RCTs (6971 participants), with most studies at unclear risk of bias. MBIs versus active comparators (29 RCTs, 2883 participants) Systolic (SBP) and diastolic (DBP) blood pressure were reported in six trials (388 participants) where heterogeneity was considerable (SBP: MD ‐6.08 mmHg, 95% CI ‐12.79 to 0.63, I2 = 88%; DBP: MD ‐5.18 mmHg, 95% CI ‐10.65 to 0.29, I2 = 91%; both outcomes based on low‐certainty evidence). There was little or no effect of MBIs on anxiety (SMD ‐0.06 units, 95% CI ‐0.25 to 0.13; I2 = 0%; 9 trials, 438 participants; moderate‐certainty evidence), or depression (SMD 0.08 units, 95% CI ‐0.08 to 0.24; I2 = 0%; 11 trials, 595 participants; moderate‐certainty evidence). Perceived stress was reduced with MBIs (SMD ‐0.24 units, 95% CI ‐0.45 to ‐0.03; I2 = 0%; P = 0.03; 6 trials, 357 participants; moderate‐certainty evidence). There was little to no effect on well‐being (SMD ‐0.18 units, 95% CI ‐0.67 to 0.32; 1 trial, 63 participants; low‐certainty evidence). There was little to no effect on smoking cessation (RR 1.45, 95% CI 0.78 to 2.68; I2 = 79%; 6 trials, 1087 participants; low‐certainty evidence). None of the trials reported CVD clinical events or adverse events. MBIs versus non‐active comparators (38 RCTs, 2905 participants) Clinical events were reported in one trial (110 participants), providing very low‐certainty evidence (RR 0.94, 95% CI 0.37 to 2.42). SBP and DBP were reduced in nine trials (379 participants) but heterogeneity was substantial (SBP: MD ‐6.62 mmHg, 95% CI ‐13.15 to ‐0.1, I2 = 87%; DBP: MD ‐3.35 mmHg, 95% CI ‐5.86 to ‐0.85, I2 = 61%; both outcomes based on low‐certainty evidence). There was low‐certainty evidence of reductions in anxiety (SMD ‐0.78 units, 95% CI ‐1.09 to ‐0.41; I2 = 61%; 9 trials, 533 participants; low‐certainty evidence), depression (SMD ‐0.66 units, 95% CI ‐0.91 to ‐0.41; I2 = 67%; 15 trials, 912 participants; low‐certainty evidence) and perceived stress (SMD ‐0.59 units, 95% CI ‐0.89 to ‐0.29; I2 = 70%; 11 trials, 708 participants; low‐certainty evidence) but heterogeneity was substantial. Well‐being increased (SMD 0.5 units, 95% CI 0.09 to 0.91; I2 = 47%; 2 trials, 198 participants; moderate‐certainty evidence). There was little to no effect on smoking cessation (RR 1.36, 95% CI 0.86 to 2.13; I2 = 0%; 2 trials, 453 participants; low‐certainty evidence). One small study (18 participants) reported two adverse events in the MBI group, which were not regarded as serious by the study investigators (RR 5.0, 95% CI 0.27 to 91.52; low‐certainty evidence). No subgroup effects were seen for SBP, DBP, anxiety, depression, or perceived stress by primary and secondary prevention. TM versus active comparators (8 RCTs, 830 participants) Clinical events were reported in one trial (201 participants) based on low‐certainty evidence (RR 0.91, 95% CI 0.56 to 1.49). SBP was reduced (MD ‐2.33 mmHg, 95% CI ‐3.99 to ‐0.68; I2 = 2%; 8 trials, 774 participants; moderate‐certainty evidence), with an uncertain effect on DBP (MD ‐1.15 mmHg, 95% CI ‐2.85 to 0.55; I2 = 53%; low‐certainty evidence). There was little or no effect on anxiety (SMD 0.06 units, 95% CI ‐0.22 to 0.33; I2 = 0%; 3 trials, 200 participants; low‐certainty evidence), depression (SMD ‐0.12 units, 95% CI ‐0.31 to 0.07; I2 = 0%; 5 trials, 421 participants; moderate‐certainty evidence), or perceived stress (SMD 0.04 units, 95% CI ‐0.49 to 0.57; I2 = 70%; 3 trials, 194 participants; very low‐certainty evidence). None of the trials reported adverse events or smoking rates. No subgroup effects were seen for SBP or DBP by primary and secondary prevention. TM versus non‐active comparators (2 RCTs, 186 participants) Two trials (139 participants) reported blood pressure, where reductions were seen in SBP (MD ‐6.34 mmHg, 95% CI ‐9.86 to ‐2.81; I2 = 0%; low‐certainty evidence) and DBP (MD ‐5.13 mmHg, 95% CI ‐9.07 to ‐1.19; I2 = 18%; very low‐certainty evidence). One trial (112 participants) reported anxiety and depression and found reductions in both (anxiety SMD ‐0.71 units, 95% CI ‐1.09 to ‐0.32; depression SMD ‐0.48 units, 95% CI ‐0.86 to ‐0.11; low‐certainty evidence). None of the trials reported CVD clinical events, adverse events, or smoking rates. Authors' conclusions Despite the large number of studies included in the review, heterogeneity was substantial for many of the outcomes, which reduced the certainty of our findings. We attempted to address this by presenting four main comparisons of MBIs or TM versus active or inactive comparators, and by subgroup analyses according to primary or secondary prevention, where there were sufficient studies. The majority of studies were small and there was unclear risk of bias for most domains. Overall, we found very little information on the effects of meditation on CVD clinical endpoints, and limited information on blood pressure and psychological outcomes, for people at risk of or with established CVD. This is a very active area of research as shown by the large number of ongoing studies, with some having been completed at the time of writing this review. The status of all ongoing studies will be formally assessed and incorporated in further updates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Owen的应助被璇璇采纳,获得10
1秒前
kuku发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
冷傲摇伽发布了新的文献求助10
2秒前
秋风的应助被科研通管家采纳,获得20
2秒前
3秒前
风吹麦浪的应助被科研通管家采纳,获得10
3秒前
3秒前
lnx的应助被科研通管家采纳,获得30
3秒前
3秒前
TED的应助被科研通管家采纳,获得10
3秒前
3秒前
在水一方的应助被科研通管家采纳,获得10
3秒前
3秒前
汉堡包的应助被科研通管家采纳,获得20
3秒前
李健的应助被科研通管家采纳,获得10
3秒前
852的应助被科研通管家采纳,获得10
3秒前
斯文败类的应助被科研通管家采纳,获得10
4秒前
4秒前
共享精神的应助被科研通管家采纳,获得10
4秒前
pluto的应助被科研通管家采纳,获得50
4秒前
传奇3的应助被科研通管家采纳,获得10
4秒前
Juvenilesy的应助被科研通管家采纳,获得10
4秒前
情怀的应助被科研通管家采纳,获得30
4秒前
null的应助被科研通管家采纳,获得10
5秒前
5秒前
Juvenilesy的应助被科研通管家采纳,获得10
5秒前
完美世界的应助被科研通管家采纳,获得10
5秒前
落寞代桃完成签到 ,获得积分10
6秒前
FashionBoy的应助被阿皮采纳,获得10
7秒前
科院er发布了新的文献求助10
7秒前
7秒前
7秒前
余香的应助被Monone采纳,获得10
8秒前
余香的应助被Monone采纳,获得10
8秒前
8秒前
mmm发布了新的文献求助10
8秒前
山上雪发布了新的文献求助30
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184422
求助须知:如何正确求助?哪些是违规求助? 9573394
关于积分的说明 21831186
捐赠科研通 7781429
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558425
邀请新用户注册赠送积分活动 2480850